Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A good read from the FDA
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm103366.pdf
If memory serves me it is dacarbazine.
http://www.aimatmelanoma.org/en/aim-for-answers/treatment-of-melanoma/fda-approved-drugs-for-melanoma/dtic-dome-dacarbazine.html
The only other drug approved for the indication PV-10 is going after is interferon which kills 15-30 patients per 400. Dacarbazine is the safer of the two. Progression free survival with DTIC is 2.7 months.
http://www.aimatmelanoma.org/en/aim-for-answers/stages-of-melanoma/stage-iii-melanoma/treatment-options-for-stage-iii-melanoma.html
Now I am not certain....but I believe...that any patients in the comparator group that fails with DTIC will be cycled to the treatment arm .
Here is what I think is going on. Recently I think Cantor decided enough is enough with sp being below $1. They stepped in and boxed it above $1. You can watch them through EDGX on level two. Then along comes buying pressure....and it is not Cantor...unless they are getting their clients in at a low price. Somebody heard something so buying increased. Cantor throws big sell orders in to cap the rise. A rapid rise on no news is bad. That attracts shorts and day traders. Now back during the great bear raid you saw massive volume through ARCX. This was the MM that the bear raid went through. If you look today ARCX is right there with the AX. The AX is EDGX. For those that don't know what an AX is....it is the MM that controls the price for the day. So if ARCX is sniffing around then maybe Cantor through EDGX is boxing it in to prevent shananagans.
The ability to box it in from a rise depends on the AX's inventory of stock to sell. If the buying pressure is large enough then the AX runs out of inventory and the sp rises until it reaches a new support. At this point if the bears wish to short the new position then the MM must be willing to be on the buying side to absorb. Before the uplisting we saw up to 30mm shares traded in a day. PVCT took on Cantor as their MM because they have the ability and depth to absorb a bear raid.
History of Dyes and Drugs and the Modern Pharma Business
http://www.cbmh.ca/index.php/cbmh/article/view/40/39
What is Rose Bengal?
It is a derivative of dichlorfluoresceine that has been treated with iodine. It was originally a wool dye. An interesting fact that prior to the boom in the dye industry in the 1800's there was no modern type of pharmas producing drugs in the way we know it now. The very first antibiotic that was synthesized was the Sulfonamides drugs. These, just like rose bengal, came from a commercial dye. When chemists started to find medical uses for dyes that started the modern pharmaceutical business.
You can read:
"Drugs Originating from the Screening of Dyes" by Dr. Walter Sneader
"Dyes and Drugs: New Uses and Implications" by Harold H. Trimm
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2465011/
Hard to say.....more like another opportunity. Nobody knows the mind of Merck but them.
Looks like EDGX is boxing in the price again. I don't think they want it to rise on no news. That would pull in short traders who would push it under a dollar again. For those of you who do not know EDGX seems to be who the PVCT market maker works through.
Now if you look closely you will notice ARCX right behind them. ARCX was the mm where the big bear raid of 2014 was run through.
I see EDGX being the ax and protecting against those who may be working through ARCX
It started out looking like the same old game....but at the end it looked different. Many different MM's were vying for position to box.....and it was not selling but accumulating. Almost like some of NYC got a whiff of something and others finally caught on. I have no clue if I am correct and I still may be faked out. Very strange trading today. I urge caution.
EDGX is trying to put a cap on the rapid rise to moderate effect.....trying to cool it down to keep the day-traders at bay I imagine.
Pump and Dump
If this is a pump and dump today then it is not very successful to short. EDGX seems to be absorbing the selling. Whoever pumped it up might have made a bit. Small Cap Street usually preceeds a SA article or a AF rant and bash.
Possible. Someone mentioned to me that combining with another drug might help them get around the alleged patent infringement. I imagine CTD will blog about it shortly.
Bristol Sues MERCK!!!!!!!!!!!
Eli Lilly may be next!!!
http://news.yahoo.com/bristol-myers-sues-merck-over-u-immunotherapy-patent-014602746--finance.html
Beware!
I don't think this recommendation by Small Cap Street is legit. This is usually a pump followed by a huge short. Everybody...heads up!
Remember the control before the uplist? Same thing going on here....MM's controlling the price for reasons known to them....maybe to get the average above a dollar for a certain length of time to keep NYSE happy.
It is not corrupt.....it is one heckuva process to make that per patient. Lots of lab work to engineer it so your immune system does not destroy it. Very very technical.
I like his outlook and agree on it. We should see India chiming in as well soon. Moffitt will be presenting new stuff in a November conference. PIII trial should start soon. New protocols for melanoma PIII and liver PII/PIII finishing up. Busy, busy, busy.
Investors buying on news and not rumor.....being pragmatic in light of past disappointments.
Starting PIII will be a solid point on the calender of events as this will solidify the start of the end.
A signed deal with China adds the credibility that everything is real that is needed.
Look for breast cancer studies to gear up since China mentions that it is the number two cancer problem for them.
Pancreatic murine study followed by lung and bladder in the works.
Cost is $150,000 per dose. Up to three doses needed. ORR is 24%. Has numerous side effects.
I am seeing very tight control over the share price. AMEX on the buy side with big blocks and EDGX on the sell side with big blocks. Basically this is saying "None Shall Pass". The last time I saw this control was with Cantor. Cantor will be trading under AMEX. There is another MM for PVCT that trades under EDGX. Somethings up. Tom123? Any ideas? Is there a TA reason to hold here for a bit?
I think it's being boxed in. You end up killing the volatility and the incentive to short and day trade it. You are telling them to move along and go manipulate somewhere else.
Are you talking about the China deal?
You are mistaken
They were never looking for a billion up front
Think tens of millions.... That's more realistic
However, for the liver and breast cancer indications you might be talking about a billion a year in sales.
From the looks of the post on the other board, it was a message to the Chinese investors saying to read all the boards and to loin the facebook page.
I don't think that word has any meaning in the Chinese language.
http://www.businessweek.com/stories/2007-05-27/the-rush-to-test-drugs-in-china
It can take a month or so....typo.
Sorry....late night playing pool.
I can take a month or so. There will be several groups and doctors looking at it. Each have to read 2000-3000 pages and then sign off on it. If there are ANY errors found then it gets sent back for correction and then sent out again. It is a painstakingly meticulous process.
Remember there are still warrants out there. Upside is that adds to the coffers.
New post on the Blog under news. An Asia publication announced the MOU so that could explain some interest today.
If you read that again he said it was worth that much for all indications but not likely to ever get that amount. He did state that there is a difference in the long time value of the drug and what they can actually get.
New Trust Intelligence
http://www.trustintelligence.com/forum/viewtopic.php?id=1929&p=16
Scroll down to the 8-23-2014 post. Good info about MOU:
PARSING THE CHINA MOU
Information & Implications
Alan Robert Ross
Trust Intelligence
August 23, 2014
New Blog Post
http://provectuspharmaceuticalsinc.blogspot.com/
Make sure to read front page and the news section on a regular basis.
Alan and Dominic seem to be really digging at the facts.
I am going to wait to let the court system call out the documents on who said what and when and why. We will all see then.
The long and torturous road as you speak of is up to 15-20 years. We are at 12 years now. If they go a full PIII then we are at the short end of normal.
They have spent less than $150 million compared to 1.5 to 5 billion for big pharma.
http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/
From a certain point of view they are ahead of the game.
What is torturous is biotech investing. Most of the public never sees what I consider "the norm". We chose, however, to get in the roller coaster. For some people it is thrilling, some throw up.
I'm going to say this again
The FDA told them to do the btd
They got the documentation that says so
The lawsuit coming up will show that
They haven't released it publicly because it would tick off the FDA
PV-10 to treat accessible lesions....immunotherapy for those not accessible.
Hey Tom123....what the heck about this?
LMAO!
http://www.thestreet.com/story/12854359/4/5-breakout-stocks-under-10-set-to-soar.html
New blog Post In News Section
http://provectuspharmaceuticalsinc.blogspot.com/p/news.html
Interesting India Fact
I credit Dominic for finding this.
Aurobindo (Datong) Bio Pharma.
It's not really based in India but was a China sub of an India company that Sinopharm bought.
The only China Pharma (Sinopharm) that has a sub doing business in India.
Interesting.
Anything I post is just a guess since no one can predict the future. This is one possible way it could play out....IF the protocols are finished by mid september then we could start to see enrollment by end of October. IF enough sites are open by then we could get 50-60 patients by end of the year. IF that happens I think the study will be recommended be shut down by the DMC end of May. IF the FDA agrees that's it....on to the NDA. So a good point for big pharma would be mid next summer. Lot's of if's, and's, or but's.
Now starting next year the big patents run out on the big pharma's. They begin to lose billions to the generics. By then Pvct should have signed deals with China and India already in place and maybe Japan, Pacific Rim, and Europe. These deals should have upfront cash, big milestone payments, and nice royalties. That monetizes the company. The licenses will be for all indications. PII/PIII liver trials should be underway as well.
Look to the companies represented on the SAB. Bayer, Pfizer, Sanofi, and Boehringer-Ingelheim as the top interested contenders for the moment. But there are two others at least that Moffitt does a lot of research for. Any combo studies with immunotherapies should pull their interest up to the top. I also see Amgen as a late sleeper, busy digesting two big purchases that I would have not swallowed.
We see the drug works and now we are seeing pharmas such as Sinopharm not only show interest but are acting on it.
The future is unknown, it has been stormy, but it looks like the sky is clearing.
The next news that should come out soon: Results from combo studies.
http://provectuspharmaceuticalsinc.blogspot.com/
Read it carefully.
It's called venting. I do it too but at a bar with Jagermeister. Some of you who follow me and know me have seen it.
I don't see a problem with the PR. But if you are a short player or a swing trader I can see the need to be negative. Give them the 90 days to ink a deal....if they do not, then berate them all the way to Tim-Buk-To.